Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

Atsushi HiraokaTakashi KumadaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraKouji JokoHiroko IijimaYoichi HiasaMasatoshi Kudonull null

Published in: Cancer reports (Hoboken, N.J.) (2021)

Atez/Bev might have therapeutic potential not only as first but also later-line treatment of existing molecular target agents. In addition, this drug combination may have less influence on hepatic function during the early period, as the present patients showed a good initial therapeutic response.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
emergency department
squamous cell carcinoma
peritoneal dialysis
combination therapy
radiation therapy
locally advanced
single molecule
rectal cancer